Quick Answer
VitaNova Life Sciences Corp reported Revenue (ASC 606) of $2.66 million for fiscal year 2025.
VitaNova Life Sciences Corp Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $2.66M | +366.5% |
| 2024 | $570.7K | +1401.8% |
| 2023 | $38.0K | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| January 31, 2026 | $709.6K | +130.2% | +66.1% |
| October 31, 2025 | $427.1K | +46.2% | +311.1% |
| July 31, 2025 | $103.9K | -4.2% | -66.3% |
| January 31, 2025 | $308.3K | +1081.3% | +5.5% |
| October 31, 2024 | $292.1K | — | +169.3% |
| July 31, 2024 | $108.5K | — | +315.6% |
| January 31, 2024 | $26.1K | — | — |
| October 31, 2023 | $0.00 | — | — |
- VitaNova Life Sciences Corp showed an increase of +366.5% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2023–2025 period, VitaNova Life Sciences Corp’s revenue (asc 606) has grown by 6905.5% (from $38.0 thousand to $2.66 million).
- The most recent figure is from VitaNova Life Sciences Corp’s fiscal year 2025 report (Form 10-K), filed with the SEC on July 24, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: